期刊
PEDIATRIC INFECTIOUS DISEASE JOURNAL
卷 37, 期 5, 页码 492-494出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/INF.0000000000001885
关键词
visceral leishmaniasis; children; treatment; liposomal amphotericin B; combination therapy
资金
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI074321, U19AI074321] Funding Source: NIH RePORTER
- NIAID NIH HHS [P50 AI074321, U19 AI074321] Funding Source: Medline
Visceral leishmaniasis affects 200-400 thousands people annually worldwide. For last few decades, there has been a steady decline in the response to pentavalent antimonial (Sbv), the drug that has been used for treating visceral leishmaniasis for almost a century. Oral miltefosine and amphotericin B are alternative drugs being been used in the treatment of leishmaniasis in children. Liposomal amphotericin B has the advantage over conventional amphotericin B is that higher doses can be given with fewer adverse effects. Liposomal amphotericin B in combination with other drugs is the preferred treatment option globally especially in Indian subcontinent. Combination therapy with multiple drugs should undergo larger clinical trials in children as these will shorten the duration of therapy, improve compliance and decrease both toxicity and drug resistance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据